Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124960 | 0.91 | NPC1 (0.50) | MAPTNPC1RAB9AKMT2AFAAH | |
| SCHEMBL5121837 | 0.90 | NPC1 (0.49) | MAPTNPC1RAB9AKMT2AFAAH | |
| SCHEMBL5125301 | 0.89 | MAPT (0.47) | MAPTNPC1RAB9AKMT2AFAAH | |
| SCHEMBL16175730 | 0.89 | TRPM8 (0.49) | MAPTFAAHSMN1; SMN2POLBTSHR | |
| SCHEMBL5130354 | 0.89 | ALDH1A1 (0.54) | MAPTFAAHSMN1; SMN2POLBTSHR | |
| SCHEMBL5128997 | 0.89 | HTT (0.47) | MAPTNPC1FAAHSMN1; SMN2ATM | |
| SCHEMBL5129896 | 0.89 | TRPM8 (0.51) | MAPTNPC1RAB9AKMT2AFAAH | |
| SCHEMBL5124351 | 0.88 | NPC1 (0.47) | MAPTNPC1RAB9AKMT2AFAAH | |
| SCHEMBL5129964 | 0.88 | SMN1; SMN2 (0.48) | MAPTNPC1RAB9AKMT2AFAAH | |
| SCHEMBL5129725 | 0.88 | EPHX2 (0.50) | NPC1RAB9AKMT2AFAAHTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | claimed |
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | claimed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | MAPT 161/4885NPC1 785/4885RAB9A 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.